Please ensure Javascript is enabled for purposes of website accessibility

Billionaire Mark Cuban's New Firm Seeks to Reduce Drug Costs

By The Daily Upside – Oct 25, 2021 at 10:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When it comes to lowering America's notoriously high prescription drug prices, who better to haggle for you than a loud-mouthed NBA team owner...

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.

When it comes to lowering America's notoriously high prescription drug prices, who better to haggle for you than a loud-mouthed NBA team owner best known for bullying referees and hosting a reality TV show?

That's Shark Tank star and Dallas Mavericks owner Mark Cuban's plan. He announced on Monday that he's entering the pharmacy-benefit manager (PMB) market, which bargains with Big Pharma over the cost of your blood pressure pills (you know, the ones you take because you're so stressed by the cost of your blood pressure pills).

Tanks a lot

The Mark Cuban Cost Plus Drug Company — yep, that's really the name — enters a sector dominated by three more colloquially monikered players: CVS' Caremark, Cigna's Express Scripts, or UnitedHealth Group's OptumRx.

And those managers are on the hot seat: several states, including Ohio, Oklahoma, Georgia, New Mexico, Kansas, Arkansas, and Mississippi are probing whether their pricing and rebate practices are transparent.

To counter those concerns, Cuban's new firm is pledging to keep its books crystal clear:

  • The company will provide every detail of its operating costs to clients, and give them 100% of the rebates it gets from drugmakers.
  • It is also launching its own online pharmacy to sell 100 of the most commonly prescribed generic medications, charging customers a 15% markup and a $3 fee on top of what it negotiates directly with generic manufacturers.

"We decided the only way to get our drugs to the people who need them is to build a parallel supply chain where we have control of all the intermediary players and ensure the same level of transparency at every level," Alex Oshmyansky, the company's CEO, told The Wall Street Journal.

A Shark's Lark: True to his reality TV form, Cuban tapped Oshmyansky, a radiologist, to run the company after he sent the billionaire a cold pitch email with the PMB idea. Who knows, it could work as well as that time Cuban spent a day managing a Dairy Queen.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.